ClinicalTrials.gg
Active, not recruitingNCT05193981HCYUpdated Apr 16, 2026

A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD

An observational study in Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
15 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic — 4 open to participants now, 7 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Mayo Clinic.

Started
2021
with 1 other
Observational
9 of 15
3 open now
Registered
12th of 15
by date

Among the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, this one is one of 2 that started in 2021, is one of 9 observational ones, and was the 12th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

4 of the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 15 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of endothelial function and injury to estimate renal disease severity and progression in patients with early Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Read the detailed description

ADPKD is a devastating systemic disorder characterized by progressive development and enlargement of bilateral renal cysts, often leading to renal failure. Disease severity and progression vary widely among patients. Large phenotypic variability, incomplete understanding of underlying mechanisms, and lack of suitable biomarkers challenge potential therapies' identification, implementation, and evaluation.

In ADPKD, systemic endothelial dysfunction (ED), characterized by an imbalance between vasodilating (particularly nitric oxide, NO) and vasoconstricting substances, develops early and correlates with renal disease severity. It has been previously associated with decreased NO availability, but NO abnormalities' mechanisms are still poorly understood. Endothelium-dependent, NO-mediated vasodilation is impaired in subjects with hyperhomocysteinemia, suggesting that NO availability is decreased in these subjects. Increased plasma levels of homocysteine have been reported in patients with ADPKD and preserved kidney function, likely contributing to a reduction in NO bioavailability. The mechanisms underlying increased homocysteine in ADPKD are not known. Furthermore, whether systemic endothelial function and injury or homocysteine levels can predict renal disease severity and progression in patients is unknown.

The investigators' broad objective is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of endothelial function and injury to estimate renal disease severity and progression in patients with early ADPKD.

Participants in this study will have a blood and a urine sample collected to determine biomarkers of oxidative stress, endothelial function and injury, homocysteine, and related metabolite levels. In addition, peripheral arterial tonometry (PAT) will determine systemic endothelial function, and an abdominal MRI will be performed to determine the patient's total kidney volume (TKV).

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease

Keywords

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • Endothelial function
  • Endothelial dysfunction
  • Homocysteine metabolism
  • Oxidative stress
  • NADPH oxidase 4 (NOX4)
04

Who can participate

Ages eligible
15 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female patients with a previous diagnosis of ADPKD that meet the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female subjects, 15-40 years of age, inclusive
  • Previous diagnosis of ADPKD (Based on Ravine et al. criteria)
  • Class 1 according to imaging classification
  • Estimated >70 mL/min/1.73m\^2(CKD-EPI)
  • Ability to provide written, .

Exclusion criteria

Exclusion Criteria:

  • Class 2 according to imaging classification
  • A concomitant systemic disease affecting the kidney
  • Diabetes mellitus
  • Predicted urine protein excretion in urinalysis >1 g/24 hrs
  • Subjects having to or interference with MRI assessments
  • Patients that are part of an interventional study or taking tolvaptan
  • Female subjects that are pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with a previous diagnosis of ADPKD

    Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria

06

What researchers measure

Primary outcomes

  1. Change in height adjusted Total kidney volume (htTKV)

    TKV determined by MRI

    Time frame: Baseline to 24 months

  2. Baseline endothelial function, homocysteine and related metabolite levels as predictors of change in TKV

    Endothelial function determined by PAT and biochemical markers, TKV determined by MRI

    Time frame: Baseline to 24 months

Secondary outcomes

  1. Change in systemic endothelial function

    Endothelial function determined by PAT

    Time frame: Baseline to 24 months

  2. Change in biochemical markers related to endothelial function and injury

    Determined by ELISA and/or biochemical assays

    Time frame: Baseline to 24 months

  3. Change in homocysteine and related metabolite levels

    Determined by 1HNMR, Mass spect, ELISA

    Time frame: Baseline to 24 months

  4. Change in Renal blood flow (RBF)

    Determined by MRI

    Time frame: Baseline to 24 months

  5. Change in estimated Glomerular filtration rate (GFR)

    eGFR determined by CKD-epi equation

    Time frame: Baseline to 24 months

  6. NADPH oxidase 4 (NOX4) expression/activity

    Determined by ELISA

    Time frame: Baseline to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2022
First posted
Jan 18, 2022
StartActual
Sep 14, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05193981
Lead sponsor
Mayo Clinic
Responsible party
Maria V. Irazabal Mira (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jan 18, 2022
Start date
Sep 14, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 16, 2026

Study contacts

Maria V Irazabal, M.D.;Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion